The study authors themselves concluded that these findings "provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss." When researchers who designed the trial reach that conclusion, it carries significant weight
health system is whether Medicaid and Medicare are prepared to treat obesity like the chronic disease it is
What started off with three core products Lemme Chill ($19.50 $30 ), Lemme Focus ($20.00 $29.99 ) and Lemme Matcha for energy ($23.99 $30 ) has quickly grown into an expansive collection of gummies, capsules and soft chews for everything from weight management ($62.99 $89.99 ) to hair growth ($34.99 $60 ), and as of May 2025 and Sept
Individuals who might theoretically be candidates for both treatments could include: Men with obesity and hypogonadism , where weight loss is a clinical priority alongside hormone replacement Transgender men on testosterone therapy who also have obesity-related metabolic conditions Individuals enrolled in clinical trials investigating retatrutide's effects on metabolic syndrome, where testosterone use is a pre-existing condition It is important to note that combining an unlicensed investigational drug with a licensed hormone therapy requires careful oversight
GLP-1R activation suppresses appetite and slows gastric emptying
Frequency: Once weekly
